Long-Term Safety Study of KW-6002 (6002-010)

Long-Term Safety Study of KW-6002 in the Treatment of Parkinson's Disease (Phase 3)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220821

Enrollment

150

Registered

2009-08-18

Start date

2009-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

investigational material(s) Generic name etc : KW-6002 INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Be willing and able to give written informed consent 2. Completion of the study 6002-009

Exclusion criteria

Exclusion criteria: 1. Mini-mental status examination score of 23 or less 2. Less than 70% of compliance in the study 6002-009 3. Emergency deviation in the study 6002-009 4. Pregnant females

Design outcomes

Primary

Measure	Time frame
Safety: adverse events	—

Secondary

Measure	Time frame
Efficacy: 24-hour patient Parkinson's diaries	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026